You are here

Identification of novel broad-spectrum Dengue antivirals

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI104106-01
Agency Tracking Number: R43AI104106
Amount: $449,400.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA12-088
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
11189 Sorrento Valley Rd, Suite 104
SAN DIEGO, CA 92121-1341
United States
DUNS: 962535782
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (760) 271-6574
Business Contact
Phone: (919) 559-3653
Research Institution

DESCRIPTION (provided by applicant): Dengue is the most common mosquito-borne viral disease in the world with no approved therapeutic treatment or vaccine to help those exposed to the virus. World Health Organization estimates that 40% of the world's population is at risk from Dengue with approximately 100 million cases annually. For the most part, Dengue is self-limiting albeit with debilitating symptoms including fever, rash, pain behind the eyes, joint and muscle pain. However, severe forms of Dengue including Hemorrhagic Fever and Dengue Shock Syndrome can occur in approximately 500,000 people leading to hospitalization each year, many of whom are children. About 2.5-5% of severe Dengue patients die each year. There are four distinct serotypes of dengueviruses that have made vaccine development a challenge. There is little to no cross immunity among the serotypes and immunity to one serotype puts an individual at risk of developing an immuno-pathological response when infected by another serotype. An alt

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government